MX2019002190A - Uso de pridopidina para tratar distonías. - Google Patents
Uso de pridopidina para tratar distonías.Info
- Publication number
- MX2019002190A MX2019002190A MX2019002190A MX2019002190A MX2019002190A MX 2019002190 A MX2019002190 A MX 2019002190A MX 2019002190 A MX2019002190 A MX 2019002190A MX 2019002190 A MX2019002190 A MX 2019002190A MX 2019002190 A MX2019002190 A MX 2019002190A
- Authority
- MX
- Mexico
- Prior art keywords
- treating
- pridopidine
- dystonias
- subject
- dystonia
- Prior art date
Links
- 208000010118 dystonia Diseases 0.000 title abstract 2
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title abstract 2
- 229950003764 pridopidine Drugs 0.000 title abstract 2
- 208000014094 Dystonic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662379175P | 2016-08-24 | 2016-08-24 | |
| US201662395319P | 2016-09-15 | 2016-09-15 | |
| PCT/US2017/048458 WO2018039475A1 (en) | 2016-08-24 | 2017-08-24 | Use of pridopidine for treating dystonias |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019002190A true MX2019002190A (es) | 2019-09-11 |
Family
ID=61246309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002190A MX2019002190A (es) | 2016-08-24 | 2017-08-24 | Uso de pridopidina para tratar distonías. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11826361B2 (enExample) |
| EP (1) | EP3503890B1 (enExample) |
| JP (2) | JP7278210B2 (enExample) |
| CN (1) | CN110012661A (enExample) |
| AU (1) | AU2017315781B2 (enExample) |
| BR (1) | BR112019003731A2 (enExample) |
| CA (1) | CA3035099C (enExample) |
| DK (1) | DK3503890T3 (enExample) |
| ES (1) | ES3009437T3 (enExample) |
| MX (1) | MX2019002190A (enExample) |
| PL (1) | PL3503890T3 (enExample) |
| WO (1) | WO2018039475A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CA2913781C (en) | 2013-06-21 | 2022-05-10 | Teva Pharmaceutical Industries Ltd. | Use of pridopidine for treating huntington's disease |
| EP3854785A1 (en) | 2015-02-25 | 2021-07-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| CN110012661A (zh) | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| CA3075020C (en) | 2017-09-08 | 2021-12-07 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| JP7585561B2 (ja) | 2019-02-04 | 2024-11-19 | プリレニア ニューロセラピューティクス リミテッド | パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン |
| AU2020243692B2 (en) | 2019-03-15 | 2023-03-02 | Prilenia Neurotherapeutics Ltd. | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
| JP7603713B2 (ja) * | 2020-05-04 | 2024-12-20 | プリレニア ニューロセラピューティクス リミテッド | 選択的ｓ１ｒアゴニストを使用するウイルス感染、疾患、又は障害の治療 |
| CN116472043A (zh) | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
| KR20250121149A (ko) * | 2022-12-27 | 2025-08-11 | 프리레니아 뉴로테라퓨틱스 엘티디. | 소아 헌팅턴병 치료를 위한 프리도피딘 |
| WO2024258929A1 (en) * | 2023-06-12 | 2024-12-19 | Unravel Biosciences, Inc. | Methods for treating diseases associated with taf1 loss of function |
| WO2025188979A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds and pridopidine for treatment of huntington's disease |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| SE0401465D0 (sv) * | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| CA2569843A1 (en) * | 2004-06-08 | 2005-12-22 | A. Carlsson Research Ab | New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
| ES2659577T3 (es) | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
| SE529246C2 (sv) * | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| MX2009011020A (es) | 2007-04-12 | 2009-10-30 | Nsab Af Neurosearch Sweden Ab | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. |
| US8562488B2 (en) * | 2009-10-05 | 2013-10-22 | The Cleveland Clinic Foundation | Systems and methods for improving motor function with assisted exercise |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| MX343620B (es) | 2011-09-07 | 2016-11-11 | Teva Pharmaceuticals Int Gmbh | Forma polimorfica de clorhidrato de pridopidina. |
| EP2787997A4 (en) * | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| US9744155B2 (en) | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
| BR112014024672A8 (pt) | 2012-04-04 | 2018-04-03 | Ivax Int Gmbh | Composições farmacêuticas para terapia de combinação |
| US20140037850A1 (en) * | 2012-08-06 | 2014-02-06 | General Electric Company | Corrosion and wear resistant organic coatings |
| CA2913781C (en) * | 2013-06-21 | 2022-05-10 | Teva Pharmaceutical Industries Ltd. | Use of pridopidine for treating huntington's disease |
| CA2937243C (en) | 2014-01-22 | 2023-07-18 | Teva Pharmaceuticals International Gmbh | Modified release formulations of pridopidine |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| EP3854785A1 (en) | 2015-02-25 | 2021-07-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| EP3324967A4 (en) | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| EP3419622B1 (en) | 2016-02-24 | 2024-03-06 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| CN110012661A (zh) | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| AU2017326436A1 (en) | 2016-09-15 | 2019-04-11 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for the treatment of anxiety and depression |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
| ES2972205T3 (es) | 2017-01-20 | 2024-06-11 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento del síndrome x frágil |
| HUE061505T2 (hu) | 2017-08-14 | 2023-07-28 | Prilenia Neurotherapeutics Ltd | Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel |
| CA3075020C (en) | 2017-09-08 | 2021-12-07 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
-
2017
- 2017-08-24 CN CN201780066796.2A patent/CN110012661A/zh active Pending
- 2017-08-24 DK DK17844432.9T patent/DK3503890T3/da active
- 2017-08-24 MX MX2019002190A patent/MX2019002190A/es unknown
- 2017-08-24 CA CA3035099A patent/CA3035099C/en active Active
- 2017-08-24 ES ES17844432T patent/ES3009437T3/es active Active
- 2017-08-24 EP EP17844432.9A patent/EP3503890B1/en active Active
- 2017-08-24 PL PL17844432.9T patent/PL3503890T3/pl unknown
- 2017-08-24 AU AU2017315781A patent/AU2017315781B2/en active Active
- 2017-08-24 WO PCT/US2017/048458 patent/WO2018039475A1/en not_active Ceased
- 2017-08-24 BR BR112019003731A patent/BR112019003731A2/pt not_active IP Right Cessation
- 2017-08-24 JP JP2019531546A patent/JP7278210B2/ja active Active
-
2019
- 2019-02-24 US US16/283,784 patent/US11826361B2/en active Active
-
2021
- 2021-05-06 JP JP2021078788A patent/JP7278327B2/ja active Active
-
2023
- 2023-10-19 US US18/489,846 patent/US12564582B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK3503890T3 (da) | 2025-01-27 |
| AU2017315781A1 (en) | 2019-04-11 |
| EP3503890A4 (en) | 2020-05-06 |
| JP2019524897A (ja) | 2019-09-05 |
| US20240075021A1 (en) | 2024-03-07 |
| US12564582B2 (en) | 2026-03-03 |
| WO2018039475A8 (en) | 2018-10-04 |
| EP3503890A1 (en) | 2019-07-03 |
| CN110012661A (zh) | 2019-07-12 |
| WO2018039475A1 (en) | 2018-03-01 |
| CA3035099A1 (en) | 2018-03-01 |
| US20190192496A1 (en) | 2019-06-27 |
| AU2017315781B2 (en) | 2021-01-28 |
| JP2021119189A (ja) | 2021-08-12 |
| JP7278327B2 (ja) | 2023-05-19 |
| ES3009437T3 (en) | 2025-03-26 |
| PL3503890T3 (pl) | 2025-03-24 |
| BR112019003731A2 (pt) | 2019-07-16 |
| EP3503890B1 (en) | 2024-12-18 |
| CA3035099C (en) | 2023-01-17 |
| JP7278210B2 (ja) | 2023-05-19 |
| US11826361B2 (en) | 2023-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018039475A8 (en) | Use of pridopidine for treating dystonias | |
| PH12019501097A1 (en) | Magl inhibitors | |
| GB2541571A (en) | Pharmaceutical compositions | |
| MX2017011997A (es) | Carbamatos de piperacina y metodos de preparacion y uso. | |
| PH12019501102A1 (en) | Magl inhibitors | |
| BR112016022855A2 (pt) | composições e métodos para modular a expressão de pkk | |
| PH12017500621A1 (en) | Triazolopyrazinones as pde1 inhibitors | |
| PH12015502075A1 (en) | Treatment of cataplexy | |
| EA201792496A1 (ru) | Способы лечения воспаления или нейропатической боли | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| PH12017501990B1 (en) | Imidazopyrazinones as pde1 inhibitors | |
| BR112019005040A2 (pt) | aplicação de pridopidina para tratamento de síndrome de rett | |
| MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
| MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
| MX382044B (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés. | |
| PH12016501495A1 (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
| TW201613610A (en) | Use of ginsenoside M1 for treating lupus nephritis | |
| NZ750581A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
| MX2018003040A (es) | Metodos para el tratamiento de formas recurrentes de esclerosis multiple. | |
| BR112018005602A2 (pt) | composição para tratar dor |